Aspirin Had No Benefit In Patients with Acute Respiratory Distress Syndrome

According to the findings of a phase II trial, using aspirin in the treatment of patients with acute respiratory distress syndrome (ARDS) has no effect on oxygenation index or other physiological outcomes.

Aspirin Had No Benefit In Patients with Acute Respiratory Distress Syndrome
Image: Woman Taking Aspirin | InStyleHealth


Patients with ARDS from five intensive care units in the UK were included in the study. For a maximum of 14 days, they were randomly assigned to receive enteral aspirin 75 mg or placebo, stratified by vasopressor demand.

The trial was called off early due to sluggish recruitment, with only 49 patients out of a total of 60 being enrolled. Twenty-four were given aspirin and the other twenty-five were given a placebo.

The aspirin group had a higher baseline APACHE II score (24.4 vs 22.0) and a lower vasopressor demand than the placebo group (58.3 percent vs 40 percent) (54.2 percent vs placebo 64 percent). The most common cause of ARDS was pneumonia, while the placebo group had more sepsis-related ARDS than the aspirin group (20.8 percent vs 40 percent). However, because the sample size was smaller than expected, the differences were said to be a result of chance.

At day 7, there was no difference in oxygenation index between the aspirin and placebo groups (unadjusted mean, 54.4 vs 42.4, respectively; mean difference, 12.0, 95 percent confidence interval [CI], –6.1 to 30.1; p=0.19).

Other respiratory physiological parameters, as well as aspirin, had no effect on the secondary outcomes. The number of adverse events that occurred (13 in each group; odds ratio, 1.04, 95 percent CI, 0.56–1.94; p=0.56) also did not differ significantly across groups.

The findings indicate that, in its current form, a bigger trial of is not possible.

 

Source: Chest 2021;10.1016/j.chest.2021.11.006

Previous Post Next Post